David Enloe, Recro Pharma CEO

Re­cro takes on big broth­er role with opi­oid ad­dic­tion drug mak­er, han­dling man­u­fac­tur­ing du­ties and ad­vis­ing on FDA work

Just three weeks ago, CD­MO Re­cro Phar­ma ex­pand­ed its foot­print to the West Coast, as it ac­quired San Diego-based Irisys for $50 mil­lion cash. The deal helped the com­pa­ny branch out in­to a broad­er set of dosage forms — and now that buy­out is al­ready bear­ing fruit.

Re­cro will serve as both an ad­vi­sor to Bio­Cor­Rx in its small mol­e­cule de­vel­op­ment for its opi­ate ad­dic­tion treat­ment drug, dubbed Bicx104, in ad­di­tion to man­u­fac­tur­ing it. The sub­cu­ta­neous pel­let of nal­trex­one has been giv­en the OK by the FDA to start in-per­son tri­als, large­ly fund­ed by the Na­tion­al In­sti­tute on Drug Abuse and the NIH.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.